Influence of Antihypertensive Treatment with Perindopril, Pindolol or Felodipin
on Plasma Leptin Concentration in Patients with Essential Hypertension

 

 Buy Article Permissions and Reprints

Abstract

Leptin - produced predominantly by adipocytes - is presumably also involved in pathogenesis of essential hypertension (EH). In the present study, we addressed the question whether and to what extent antihypertensive monotherapy does influence leptinemia in patients with mild or moderate EH. Forty-two EH patients were enrolled in this randomized, open-labeled study. In all subjects, plasma concentrations of leptin, insulin, glucose, cholesterol, triglycerides and creatinine were estimated twice - before and one month after initiation of monotherapy with perindopril, pindolol or felodipin, respectively. Plasma leptin concentration, in the afternoon and midnight, was significantly higher in patients with essential hypertension than in normotensive healthy subjects (p < 0.01). Therapy with perindopril or felodipin did not influence the daily profile of leptinemia or insulinemia, respectively. However, pindolol monotherapy showed a marked (p < 0.01) suppressive effect on the daily profile of leptinemia, but did not influence insulinemia. Conclusions: First, patients with essential hypertension are characterized by higher plasma leptin levels as compared with normotensive healthy subjects; second, suppressive effect of pindolol on leptinemia may be of pathophysiological relevance in the course of weight gain during β-blocker therapy.

References

• 1 Elisaf M. The treatment of coronary heart disease: an update. Part 1: An overview of the risk factors for cardiovascular disease.  Curr Med Res Opin. 2001;  17 18-28
  CrossrefPubMedGoogle Scholar
• 2 Rimm B, Stampfer M J, Giovannucci E, Ascherio A, Spiegelman D, Colditz G A, Willett W C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.  Am J Epidemiol. 1995;  141 1117-1127
  PubMedGoogle Scholar
• 3 Kannel W B, Brand M, Skinner J J, Dawber T R, Mc Namara P M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study.  Ann Intern Med. 1967;  67 48-59
  PubMedGoogle Scholar
• 4 MacMahon S W, Blacket R B, Macdonald G J, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.  J Hypertens. 1984;  2 85-91
  PubMedGoogle Scholar
• 5 Ahima R S, Flier J S. Adipose tissue as an endocrine organ.  Trends Endocrinol Metab. 2000;  11 327-332
  PubMedGoogle Scholar
• 6 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
  CrossrefPubMedGoogle Scholar
• 7 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
  CrossrefPubMedGoogle Scholar
• 8 Hall J E, Shek E WM, Brands M W. Does leptin contribute to obesity hypertension?.  Curr Opin Endocrinol Diabetes. 1999;  6 225-229
  CrossrefPubMedGoogle Scholar
• 9 Mark A L, Correia M LG, Rahmouni K, Haynes W G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications.  J Hypertens. 2002;  20 1245-1250
  CrossrefPubMedGoogle Scholar
• 10 Agata J, Masuda A, Takada M, Hagishiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension.  Am J Hypertens. 1997;  10 1171-1174
  CrossrefPubMedGoogle Scholar
• 11 Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H, Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents.  J Hypertens. 1998;  16 2007-2012
  PubMedGoogle Scholar
• 12 Suter P M, Locher R, Häsler E, Vetter W. Is there a role of the ob gene product leptin in essential hypertension?.  Am J Hypertens. 1998;  11 1305-1311
  CrossrefPubMedGoogle Scholar
• 13 Kokot F, Adamczak M, Wiežcek A, Cieplok J. Does leptin play a role in the pathogenesis of essential hypertension?.  Kidney Blood Pres Res. 1999;  22 154-160
  PubMedGoogle Scholar
• 14 Adamczak M, Kokot F, Wiežcek A. Relationship between plasma renin profile and leptinaemia in patients with essential hypertension.  J Hum Hypertens. 2000;  14 503-509
  CrossrefPubMedGoogle Scholar
• 15 Saad M F, Riad-Gabriel M G, Khan A, Sharma A, Michael R, Jinagouda S D, Boyadjian R, Steil G M. Diurnal and ultradian rhythmicity of plasma leptin: effect of gender and adiposity.  J Clin Endocrinol Metab. 1998;  83 1706-1712
  CrossrefPubMedGoogle Scholar
• 16 Jones D W. Body weight and blood pressure. Effects of weight reduction on hypertension.  Am J Hypertens. 1996;  9 50S-54S
  CrossrefPubMedGoogle Scholar
• 17 Tuck M L, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure. Plasma renin activity and plasma aldosterone levels in obese patients.  N Engl J Med. 1981;  304 930-933
  CrossrefPubMedGoogle Scholar
• 18 Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension.  J Hypertens. 1999;  17 151-183
  PubMedGoogle Scholar
• 19 Joint National Committee on Prevation, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Sixth report.  Arch Intern Med. 1997;  157 2413-2446
  CrossrefPubMedGoogle Scholar
• 20 Kokot F, Wiežcek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, Trembecki J. Function of endocrine organs in hemodialyzed patients on long-term erythropoietin therapy.  Artif Organs. 1995;  19 428-435
  PubMedGoogle Scholar
• 21 Kalsbeek A, Fliers E, Romijn J A, La Fleur S E, Wortel J, Bakker O, Endert E, Buijs R M. The suprachiasmatic nucleus generates the diurnal changes in plasma leptin levels.  Endocrinology. 2001;  142 2677-2685
  CrossrefPubMedGoogle Scholar
• 22 Corica F, Corsonello A, Lentile R, de Gregorio T, Malara A, Artemisia A, Buemi M. Leptin and norepinephrine plasma concentrations during glucose loading in normotensive and hypertensive obese women.  Am J Hypertens. 2001;  9 50S-54S
  PubMedGoogle Scholar
• 23 Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.  J Renin Angiotensin Aldosterone Syst. 2001;  2 112-116
  PubMedGoogle Scholar
• 24 Matsuo K, Mikami H, Ogihara T, Tuck M L. Weight reduction and pharmacologic treatment in obese hypertensives.  Am J Hypertens. 2001;  14 530-538
  CrossrefPubMedGoogle Scholar
• 25 Kim S, Whelan J, Claycombe K, Reath D B, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3Ts-L1 and human adipocytes via a prostaglandin-independent mechanism.  J Nutr. 2002;  132 1135-1140
  PubMedGoogle Scholar
• 26 Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group.  Cardiovasc Drugs Ther. 2000;  14 67-75
  CrossrefPubMedGoogle Scholar
• 27 Cammisotto P G, Bukowiecki L J. Mechanisms of leptin secretion from white adipocytes.  Am J Physiol Cell Physiol. 2002;  283 C244-C250
  PubMedGoogle Scholar
• 28 Pinkey J H, Coppack S W, Mohamed Ali V. Effect of isoprenaline on plasma leptin and lipolysis in humans.  Clin Endocrinol (Oxf). 1998;  48 407-411
  CrossrefPubMedGoogle Scholar
• 29 Carruli L, Ferrari S, Bertolini M, Tagliafico E, Del Rio G. Regulation of ob gene expression: evidence for epinephrine-induced suppression in human obesity.  J Clin Endocrinol Metab. 1999;  84 3309-3312
  CrossrefPubMedGoogle Scholar
• 30 Bottner A, Eisenhofer G, Torpy D J, Ehrhart-Bornstein M, Keiser H R, Chrousos G P, Bornstein S R. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients.  Metabolism. 1999;  48 543-545
  CrossrefPubMedGoogle Scholar
• 31 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.  Hypertension. 2001;  37 250-254
  CrossrefPubMedGoogle Scholar
• 32 Kunz I, Schorr U, Klaus S, Sharma A M. Resting metabolic rate and substrate use in obesity hypertension.  Hypertension. 2000;  36 26-32
  PubMedGoogle Scholar
• 33 Astrup A, Simonsen L, Bulow J, Madsen J, Christensen N J. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle.  Am J Physiol. 1989;  257 E340-E345
  PubMedGoogle Scholar
• 34 Ravussin E, Pratley R E, Maffei M, Wang H, Friedman J M, Bennett P H, Bogardus C. Relatively low plasma leptin concentration precedes weight gain in Pima Indians.  Nature Med. 1997;  3 238-240
  PubMedGoogle Scholar
• 35 Mavri A, Stegnar M, Sabovic M. Do vaseline serum leptin levels predict weight regain after dieting in obese women?.  Diab Obes Metab. 2001;  3 293-298
  PubMedGoogle Scholar
• 36 Schmieder R E, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment.  Br Med J. 1992;  307 537-540
  PubMedGoogle Scholar
• 37 Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.  Horm Metab Res. 2001;  33 167-169
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in double-blind cross-over study in hypertensive patients.  Blood Press. 1992;  1 92-101
  PubMedGoogle Scholar
• 39 Reneland R, Alvarez E, Andrersson P E, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long treatment with atenolol or trandolapril.  J Hum Hypertens. 2000;  14 175-180
  CrossrefPubMedGoogle Scholar

Prof. Dr. hab. med. A. Wiežcek

Department of Nephrology, Endocrinology and Metabolic Diseases ·

Silesian University School of Medicine · Francuska Str. 20 - 24 · 40-027 Katowice · Poland ·

Phone: + 48 (32) 255 26 95

Fax: + 48 (32) 255 37 26

Email: awiecek@spskm.katowice.pl